
Opinion|Videos|January 13, 2025
Looking Ahead: Ph+ ALL in 2025 and Beyond
Dr. Bijal Shah offers forward-looking perspectives on the future of Ph+ ALL treatment, highlighting potential advancements, emerging challenges, and opportunities for improving patient care in 2025 and beyond.
Advertisement
- Closing thoughts
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Mirvetuximab Soravtansine Demonstrates Promising Efficacy, Safety in Platinum-Resistant Recurrent Ovarian Cancer
2
How Artificial Intelligence Is Transforming Leukemia Detection and Diagnosis
3
Zanubrutinib Shows Similar Efficacy but Better Safety Than VEN–I in Frontline CLL
4
FDA Approves Sibeprenlimab for Immunoglobulin A Nephropathy
5













































